Download PDF
Endoscopy 2014; 46(12): 1101-1105
DOI: 10.1055/s-0034-1377632
Innovations and brief communications
© Georg Thieme Verlag KG Stuttgart · New York

A new fully covered metal stent with anti-migration features for the treatment of malignant dysphagia

Daisy Walter
1   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Maarten W. van den Berg
2   Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
,
Jeanin E. van Hooft
2   Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
,
Henk Boot
3   Department of Gastroenterology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
,
Robert C. H. Scheffer
4   Department of Gastroenterology, Jeroen Bosch Hospital, Den Bosch, The Netherlands
,
Frank P. Vleggaar
1   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Peter D. Siersema
1   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

submitted29 January 2014

accepted after revision20 June 2014

Publication Date:
30 September 2014 (online)

Also available at
    Permissions and Reprints

Background and study aims: A new esophageal stent with two anti-migration features was developed to minimize migration. The aim of this study was to evaluate the clinical efficacy and safety of this stent in patients with malignant dysphagia.

Patients and methods: A total of 40 patients with dysphagia due to a malignant obstruction of the esophagus were prospectively enrolled in this cohort study.

Results: Stent placement was technically successful in 39 patients (98 %). The median dysphagia-free time after stent placement was 220 days (95 % confidence interval 94 – 345 days). Nine patients (23 %) experienced recurrent dysphagia due to tissue overgrowth (n = 2), stent fracture (n = 1), and partial (n = 5) or complete (n = 1) stent migration. A total of 16 serious adverse events occurred in 14 patients (36 %), with hemorrhage (n = 3) and severe nausea or vomiting (n = 3) being the most common causes.

Conclusions: This new stent design was effective for the palliation of malignant dysphagia and had a low rate of recurrent dysphagia. However, despite the anti-migration features, stent migration was still a major cause of recurrent dysphagia. Furthermore, treatment was associated with a high adverse event rate.

Dutch Trial Registration (NTR 3313)

 

  • References

  • 1 Sundelof M, Ye W, Dickman PW et al. Improved survival in both histologic types of oesophageal cancer in Sweden. Int J Cancer 2002; 99: 751-754
    CrossrefPubMedGoogle Scholar
  • 2 Homs MY, Steyerberg EW, Kuipers EJ et al. Causes and treatment of recurrent dysphagia after self-expanding metal stent placement for palliation of esophageal carcinoma. Endoscopy 2004; 36: 880-886
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Hirdes MM, Vleggaar FP, Siersema PD. Stent placement for esophageal strictures: an update. Expert Rev Med Devices 2011; 8: 733-755
    CrossrefPubMedGoogle Scholar
  • 4 Verschuur EM, Steyerberg EW, Kuipers EJ et al. Effect of stent size on complications and recurrent dysphagia in patients with esophageal or gastric cardia cancer. Gastrointest Endosc 2007; 65: 592-601
    CrossrefPubMedGoogle Scholar
  • 5 Verschuur EM, Repici A, Kuipers EJ et al. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol 2008; 103: 304-312
    CrossrefPubMedGoogle Scholar
  • 6 Homs MY, Steyerberg EW, Eijkenboom WM et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364: 1497-1504
    CrossrefPubMedGoogle Scholar
  • 7 van Boeckel PG, Repici A, Vleggaar FP et al. A new metal stent with a controlled-release system for palliation of malignant dysphagia: a prospective, multicenter study. Gastrointest Endosc 2010; 71: 455-460
    CrossrefPubMedGoogle Scholar
  • 8 Vakil N, Morris AI, Marcon N et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 2001; 96: 1791-1796
    CrossrefPubMedGoogle Scholar
  • 9 Hirdes MM, Siersema PD, Vleggaar FP. A new fully covered metal stent for the treatment of benign and malignant dysphagia: a prospective follow-up study. Gastrointest Endosc 2012; 75: 712-718
    CrossrefPubMedGoogle Scholar
  • 10 Kim ES, Jeon SW, Park SY et al. Comparison of double-layered and covered Niti-S stents for palliation of malignant dysphagia. J Gastroenterol Hepatol 2009; 24: 114-119
    CrossrefPubMedGoogle Scholar
  • 11 Uitdehaag MJ, van Hooft JE, Verschuur EM et al. A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study. Gastrointest Endosc 2009; 70: 1082-1089
    CrossrefPubMedGoogle Scholar
  • 12 Verschuur EM, Homs MY, Steyerberg EW et al. A new esophageal stent design (Niti-S stent) for the prevention of migration: a prospective study in 42 patients. Gastrointest Endosc 2006; 63: 134-140
    CrossrefPubMedGoogle Scholar
  • 13 Hirdes MM, van Hooft JE, Wijrdeman HK et al. Combination of biodegradable stent placement and single-dose brachytherapy is associated with an unacceptably high complication rate in the treatment of dysphagia from esophageal cancer. Gastrointest Endosc 2012; 76: 267-274
    CrossrefPubMedGoogle Scholar
  • 14 Hirdes MM, Vleggaar FP, de Beule M et al. In vitro evaluation of the radial and axial force of self-expanding esophageal stents. Endoscopy 2013; 45: 997-1005
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Siersema PD. New developments in palliative therapy. Best Pract Res Clin Gastroenterol 2006; 20: 959-978
    CrossrefPubMedGoogle Scholar